|
Follow-up of the patients (n = 5): psychiatric symptoms, CD activity, and amino acidconcentrations [median (min-max)]. |
|||||
| 0 (baseline) |
≥1<1.5 months1) |
p-value2) |
≥3 months |
p-value2) |
|
|
|
|||||
| CBCL Total problems |
34 (9–39) |
21 (8–29) |
** |
21 (2–22) |
** |
| YSR Total problems |
20 (9–36) |
11 (5–41) |
n.s. |
2 (0–22) |
** |
| S-tTGAbA |
42 (10–310) |
5 (3–51) |
** |
3 (1–17) |
** |
| Prolactin3) |
1100 (635–2850) |
256 (127–282) |
n.s * |
244 (110–565) |
** |
| L-tyrosine4) |
33 (26–44) |
39 (37–70) |
n.s * |
40 (38–47) |
** |
| CAA5) |
353 (316–441) |
401 (368–657) |
n.s * |
395 (367–568) |
** |
| L-tryptophan4) |
40 (32–51) |
52 (45–66) |
n.s * |
46 (36–59) |
n.s. |
| Tryptophan/CAA6) |
11.3 (10.1–14.9) |
12.0 (10.1–14.1) |
n.s. |
10.1 (9.5–12.5) |
n.s. |
| Free L-tryptophan 4) |
4.9 (4.5–11.8) |
8.4 (5.3–10.9) |
n.s * |
10.6 (5.0–19.0) |
n.s. * 7) |
| Free tryptophan/CAA6) |
1.4 (1.0–3.5) |
1.9 (1.0–3.0) |
n.s. |
2.6 (1.3–3.4) |
n.s. |
|
1) amino acid concentrations; n = 4; 2) Wilcoxon signed – ranks test: compared with baseline; ** = P < 0.05; * = P ≥ 0.05 < 0.07; 3) mU/l; normal: females 50–300, males 50–500; 4) pmol/μl; 5) L-valine, L-leucine, L-isoleucine, L-phenylalanine, L-tyrosine; pmol/μl; 6) 100 × pmol/μl: pmol/μl; 7) repeated Measures Friedman test, n = 4, P = 0.050 | |||||
Pynnönen et al. BMC Psychiatry 2005 5:14 doi:10.1186/1471-244X-5-14 |
|||||